Peripheral T-cell lymphomas represent 10% to 15% of non-Hodgkin lymphomas and comprise more than 20 different entities. Treatment of very rare T-cell lymphomas can be challenging because there are no large or randomized studies to guide clinical decision making, and treatment paradigms are often based on small series or imperfect data. Although a strict algorithm cannot be written with certainty, through the literature that exists and clinical experience, themes and principles of approaches do emerge that when coupled with clinical judgment allow reasonable and logical decisions.
Key points
- •
Peripheral T-cell lymphomas represent 10% to 15% of non-Hodgkin lymphomas and comprise more than 20 different entities.
- •
Treatment of very rare T-cell lymphomas can be challenging because there are no large or randomized studies to guide clinical decision making and treatment paradigms are often based on small series or imperfect data.
- •
Although a strict algorithm cannot be written with certainty, through the literature that exists and clinical experience, themes and principles of approaches do emerge that when coupled with clinical judgment allow reasonable and logical decisions.
Related posts:
Peripheral T-Cell Lymphoma: The Beginning of the End of the Beginning
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Adult T-cell Leukemia/Lymphoma
Mycosis Fungoides and Sezary Syndrome
Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas
Angioimmunoblastic T-Cell Lymphoma
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
